IVF Hartmann Holding AG’s (VTX:VBSN) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver’s Seat?

Most readers would already know that IVF Hartmann Holding’s (VTX:VBSN) stock increased by 7.8% over the past three months. Given that stock prices are usually aligned with a company’s financial performance in the long-term, we decided to investigate if the company’s decent financials had a hand to play in the recent price move. In this article, we decided to focus on IVF Hartmann Holding’s ROE.

ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

Check out our latest analysis for IVF Hartmann Holding

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders’ Equity

So, based on the above formula, the ROE for IVF Hartmann Holding is:

12% = CHF18m ÷ CHF141m (Based on the trailing twelve months to June 2024).

The ‘return’ is the amount earned after tax over the last twelve months. That means that for every CHF1 worth of shareholders’ equity, the company generated CHF0.12 in profit.

We have already established that ROE serves as an efficient profit-generating gauge for a company’s future earnings. We now need to evaluate how much profit the company reinvests or “retains” for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes.

At first glance, IVF Hartmann Holding seems to have a decent ROE. Even when compared to the industry average of 12% the company’s ROE looks quite decent. Given the circumstances, we can’t help but wonder why IVF Hartmann Holding saw little to no growth in the past five years. Based on this, we feel that there might be other reasons which haven’t been discussed so far in this article that could be hampering the company’s growth. Such as, the company pays out a huge portion of its earnings as dividends, or is faced with competitive pressures.

We then compared IVF Hartmann Holding’s net income growth with the industry and found that the company’s growth figure is lower than the average industry growth rate of 11% in the same 5-year period, which is a bit concerning.

Earnings growth is a huge factor in stock valuation. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. If you’re wondering about IVF Hartmann Holding’s’s valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.